Which drug companies face the most patent expirations?

DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
See Plans and Pricing
Database preview Discount schedule Contact

Share:

This chart shows which pharmaceutical companies face the most patent expirations this year. The drug companies facing the most patent expirations this year are Merck, Sanofi Aventis Us, Glaxosmithkline, Abbvie, Abraxis Bioscience, Genzyme, Abbott Endocrine, Boehringer Ingelheim, Merck And Co Inc, and Vyteris.

Pharmaceutical Companies Facing the Most Expirations in 2013